Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases.

ABSTRACT: Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gastrointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogeneity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient's response to therapies and that could help them in choosing what drug to administer. Several candidate biom

SUBMITTER: Privitera G 

PROVIDER: S-EPMC7922976 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature